369 related articles for article (PubMed ID: 26349590)
1. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
2. Rectal dose constraints for salvage iodine-125 prostate brachytherapy.
Peters M; Hoekstra CJ; van der Voort van Zyp JR; Westendorp H; van de Pol SM; Moerland MA; Maenhout M; Kattevilder R; van Vulpen M
Brachytherapy; 2016; 15(1):85-93. PubMed ID: 26614233
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
6. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.
Rose JN; Crook JM; Pickles T; Keyes M; Morris WJ
Brachytherapy; 2015; 14(3):342-9. PubMed ID: 25727178
[TBL] [Abstract][Full Text] [Related]
7. Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
Groen VH; van Schie M; Zuithoff NPA; Monninkhof EM; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; Pos FJ; Smeenk RJ; Haustermans K; Isebaert S; Draulans C; Depuydt T; Verkooijen HM; van der Heide UA; Kerkmeijer LGW
Radiother Oncol; 2022 Feb; 167():127-132. PubMed ID: 34968470
[TBL] [Abstract][Full Text] [Related]
8. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
[TBL] [Abstract][Full Text] [Related]
9. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Gocho T; Hori M; Fukushima Y; Someya M; Kitagawa M; Hasegawa T; Tsuchiya T; Hareyama M; Takagi M; Hashimoto K; Masumori N; Sakata KI
Brachytherapy; 2020; 19(3):290-297. PubMed ID: 32249179
[TBL] [Abstract][Full Text] [Related]
11. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
[TBL] [Abstract][Full Text] [Related]
12. The dosimetry of prostate brachytherapy-induced urethral strictures.
Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
14. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
15. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
[TBL] [Abstract][Full Text] [Related]
16. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M; Maenhout M; van der Voort van Zyp JR; Moerland MA; Moman MR; Steuten LM; van Deursen MJ; van Vulpen M
Radiother Oncol; 2014 Jul; 112(1):77-82. PubMed ID: 24998704
[TBL] [Abstract][Full Text] [Related]
17. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
Thomas C; Keyes M; Liu M; Moravan V
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
[TBL] [Abstract][Full Text] [Related]
18. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
[TBL] [Abstract][Full Text] [Related]
19. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
20. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]